J&J to acquire Momenta for $6.5 billion by Selina McKee | Aug 21, 2020 | News | 0 The move will expand Janssen’s presence in autoimmune diseases Read More
Shire steps away from biosimilars by Selina McKee | Sep 28, 2016 | News | 0 Shire has handed back rights to the two biosimilars it acquired through its recent purchase of Baxalta, retaining its focus on the development of drugs for rare diseases. Read More